The drugmaker plans higher-dose and oral obesity treatments for India, with oral semaglutide likely arriving by mid-2027 as competition heats up.
Recap by typeshit. Full story at The Financial Express.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Wilkinson posts a draft chart to guide anaesthesia decisions and notes the evidence is mixed. It is not clear GLP-1 drugs are the focus.
Users report migraines, eye pain and fatigue from experimental peptides, just as Health Secretary RFK Jr. moves to loosen access to them.
Loading…